BONESUPPORT'S CEO SELLS SHARES - REMAINS SIGNIFICANT LONG-TERM OWNER

Published: 2022-07-19

BONESUPPORT™, a leading company in orthobiologics for the management of bone injuries, today announced that Emil Billbäck, CEO of BONESUPPORT, has sold 92,450 shares in BONESUPPORT.

After the sale, Emil Billbäck owns 344,230 shares and thus remains with a larger private ownership.

"The sale is made solely to cover tax obligations and I do not plan to sell additional shares. I have great confidence in BONESUPPORT's future prospects and look forward to continuing to develop the company", says Emil Billbäck, CEO of BONESUPPORT.

The transaction has been reported to the Swedish Financial Supervisory Authority in accordance with current regulations.

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 213 million in 2021. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.